How to prioritize treatment in dual malignancy: A case report of patient with non-Hodgkin lymphoma and breast cancer.
Ann Med Surg (Lond)
; 81: 104300, 2022 Sep.
Article
in English
| MEDLINE | ID: covidwho-1966317
ABSTRACT
Introduction:
Clinicians often encounter dilemma upon treating multiple primary malignancies. Case presentation We report a case of a female patient, 72, complained of a lump under her left eye since January 2019. Patient was diagnosed with infiltrating ductal carcinoma grade III of the right breast in June 2018 with ER+, PR+, and HER2-, treated with hormonal treatment. Histopathology examination of the lump revealed Non Hodgkin Lymphoma (NHL), B cell type, high grade. Patients received rituximab, cyclophosphamide, epirubicin, vincristin, and prednisone (RHCOP) for 6 cycles to overcome lymphoma then received hormonal therapy afterwards. Clinicaldiscussion:
According to earlier published case reports, it's advised to start hormonal therapy after RHCOP. The survival time was 21 months (5.1-114.7 months) with 5-year overall survival 29.Conclusion:
Unfortunately, we could not have a follow-up on the patient after finishing 6 cycles of RHCOP due to the COVID-19 pandemic situation.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
/
Cohort study
/
Prognostic study
Language:
English
Journal:
Ann Med Surg (Lond)
Year:
2022
Document Type:
Article
Affiliation country:
J.amsu.2022.104300
Similar
MEDLINE
...
LILACS
LIS